ClinicalTrials.gg
CompletedNCT07114419Updated Nov 18, 2026

The Efficacy and Safety of Efsubaglutide Alfa in Overweight/Obesity(SPARKLE)

A Phase 2 interventional study of Efsubaglutide Alfa 20 mg QW and Efsubaglutide Alfa 40 mg QW in Obesity and Overweight, sponsored by Shanghai Yinnuo Pharmaceutical Technology Co., Ltd.. Completed at 5 sites in Australia. Open to participants aged 18 Years to 75 Years. Per ClinicalTrials.gov, last updated 2026-11-18.

Sponsored by Shanghai Yinnuo Pharmaceutical Technology Co., Ltd. · Phase 2, Interventional, and Treatment

How we know

Updated Nov 18, 2026Now CompletedPrimary completion moved+2 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
200
Allocation
Randomized
Ages
18 Years to 75 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 188 studies in Obesity with a site in Australia — 56 open to participants now, 74 under way, 34 of them phase 3. Obesity · Australia.

Enrollment
81st of 169
200 · median 180
Started
2025
with 24 others
Phase 2
27 of 188
4 open now
Registered
137th of 188
by date

Among the 188 studies in Obesity with a site in Australia, this one is the 81st largest by enrollment of the 169 interventional ones that give a count, is one of 25 that started in 2025, is one of 27 in phase 2, and was the 137th registered.

Obesity

11,564 studies on the registry are indexed under Obesity; 2,063 are open to participants now.

Browse Obesity studies →

Open to participants now

56 of the 188 studies in Obesity with a site in Australia are open now. Recruiting first, the newest first:

51 more — sign in →

All 56 open studies →

A study can be open while its sites in Australia have not opened yet or have stopped. Only those recruiting at a site in Australia →

Who these studies take

Of the 1,352 Obesity studies recruiting now, 382 (28%) set no upper age limit and 867 (64%) stop at 75 or younger; 169 take children under 18; 491 take healthy volunteers.

This study: 18 Years to 75 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 188 studies in Obesity with a site in Australia, or all of them as a file.
02

Study summary

This is a multicenter, double-blind, randomized, placebo-controlled phase Ⅱ study to evaluate the efficacy, safety, pharmacokinetics, and immunogenicity of YN-011 in subjects with overweight (27 kg/m2 ≤ BMI \< 30 kg/m2, with at least one comorbidity) or obesity (BMI ≥ 30 kg/m2, with or without comorbidities). The entire study period will consist of a 2-week screening period, a 22-week double-blind treatment period, and a 4-week off-treatment follow-up period

03

Conditions studied

  • Obesity and Overweight
04

Who can participate

Ages eligible
18 Years to 75 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Willing to comply with protocol required visit schedule and visit requirements and provide written form (ICF);
  2. Male or female subjects, aged 18 to 75 years (both inclusive) at the time of signing the ICF;
  3. Obese: ≥ 30.0 kg/m2, with or without comorbidities; Or overweight: 27.0 kg/m2 ≤ BMI \< 30.0 kg/m2, with at least one of the following weight-related comorbidities: pre-diabetes, hypertension, dyslipidemia, fatty liver, osteoarthritis, or obesity-induced obstructive sleep apnea syndrome (If the subject has only fatty liver as a comorbidity, imaging results within the 3 months prior to screening are required for fatty liver);
  4. A self-reported change in body weight less than 5.0% controlled with diet and exercise within 3 months before screening;
  5. Women of (WOCBP) and fertile males with WOCBP partners must use highly effective methods throughout the study (from the signing of ICF to 3 months after the last dose of medicinal products).

Exclusion criteria

Exclusion Criteria:

  1. Obesity caused by endocrine disease or monogenic mutation, including but not limited to hypothalamic obesity, pituitary obesity, hypothyroidism-related obesity, Cushing's syndrome, insulinoma, acromegaly or hypogonadism;
  2. Known or suspected allergy to the medicinal product, its components or drugs of the same class;
  3. Previously diagnosed diabetes mellitus (including type 1 diabetes mellitus, type 2 diabetes mellitus, diabetes mellitus due to pancreatic damage, or other types of diabetes mellitus [except gestational diabetes mellitus]);
  4. History of severe gastrointestinal disease (e.g., active ulcers), or gastrointestinal surgery (except for appendectomy, cholecystectomy, or other gastrointestinal endoscopic surgeries deemed by the investigator to have no significant impact on gastrointestinal motility), or gastric emptying abnormalities (e.g., pyloric obstruction, gastroparesis), or long-term use of drugs with direct effects on gastrointestinal motility within 6 months before screening, or those who were not suitable for participating in this study at the investigator's discretion;
  5. History of significant cardiovascular or cerebrovascular disease within 6 months before screening, including but not limited to:1) Myocardial infarction, coronary angioplasty or bypass grafting, heart valve disease or heart valve repair, clinically significant arrhythmias requiring treatment, angina, , cerebrovascular accident or others; 2)Congestive heart failure classified as Grade III or IV by the (NYHA) (refer to Appendix 3);
  6. History of acute or chronic pancreatitis, symptomatic gallbladder disease (subjects who have undergone cholecystectomy and have stable condition post-surgery are excluded), or pancreatic injury and other factors that may lead to high risk of pancreatitis;
  7. Presence of hyperthyroidism; or hypothyroidism that has not been controlled with a stable medication dose (defined as a stable dose for 3 months or longer);
  8. Personal or family history of medullary thyroid carcinoma (MTC) or multiple endocrine neoplasia type 2 (MEN2);
  9. Subjects who have experienced two or more hypoglycemic events within 6 months prior to screening, defined as blood glucose \< 2.8 mmol/L (50.4 mg/dl) or blood glucose not reaching \< 2.8 mmol/L (50.4 mg/dl) but with significant hypoglycemia symptoms (manifested by sympathetic arousal [e.g., palpitations, anxiety, sweating, dizziness, shaking of the hands, feeling of hunger, etc.] and CNS symptoms [e.g., altered mentation, cognitive disturbances, seizures and coma]);
  10. History of an active or untreated or are in remission from a clinically significant malignancy (other than basal- or squamous-cell skin cancer, in situ carcinomas of the cervix, or in situ prostate cancer) for less than 5 years; or there is a potential malignancy during screening;
  11. History of severe infection or severe trauma within 3 months prior to screening, or undergoing major surgery or not fully recovering from surgery, and the investigator determines that the participant is unsuitable for this study;
  12. History of significant active or unstable major depressive disorder or other severe psychiatric disorder (for example, schizophrenia, bipolar disorder, or other serious mood or anxiety disorder) within 2 years prior to screening;
  13. Previous suicidal tendency or suicidal behavior;
  14. Suicidal ideation corresponding to type 4 or 5 on the C-SSRS at screening;
  15. PHQ-9 questionnaire ≥ 15 points at screening;
  16. Known active infections, e.g., bacterial, fungal and viral infections, including: 1) (HIV) infection: defined as HIV antibody positive; 2)Syphilis infection: defined as treponema pallidum antibody (TP-Ab) positive; 3)Active virus (HBV): defined as hepatitis B surface antigen (HBsAg) positive and HBV-deoxyribonucleic acid (DNA) ≥ lab-specific (ULN) (for those with positive result on HBsAg, HBV DNA test will be performed and those with positive HBV DNA results will be excluded); 4)Active virus (HCV): defined as HCV antibody (HCV-Ab) positive and HCV-ribonucleic acid (RNA) positive, if HCV-Ab positive and HCV RNA negative can be considered as eligible at the discretion of the Investigator;
  17. Any of the laboratory test results at screening meet the following criteria (if there is a clear reason for re-test, the re-test can be performed once during the screening period, and the investigator should record the reason for re-test): 1) ≥ 6.5% or fasting blood glucose ≥ 7.0 mmol/L (126 mg/dL) (fasting blood glucose will be tested at the local laboratory at the time of screening, plasma or serum glucose is acceptable); 2)Thyroid stimulating hormone (TSH) > 6.0 mIU/L or \< 0.4 mIU/L; 3) or AST ≥ 3.0×ULN or total (TBIL) ≥ 2× ULN; 4)Fasting TG > 5.65 mmol/L (500 mg/dl); 5)Blood amylase or lipase > 2.0×ULN; 6)Calcitonin ≥ 50 ng/L(pg/mL); 7)Estimated (eGFR) ≤ 30 mL/min/1.73m2, calculated by the CKD-EPI formula (refer to Appendix 4); 8) (INR) > ULN;
  18. Abnormal 12-lead : second- or third-degree atrioventricular block, long syndrome or QTcF > 450 ms (males) or > 470 ms (females) (refer to Appendix 5), left bundle branch block, Wolff-Parkinson-White syndrome, or other clinically significant abnormalities that require treatment;
  19. Uncontrolled hypertension, defined as systolic blood pressure ≥ 160 mmHg and/or diastolic blood pressure ≥ 100 mmHg;
  20. Use of any of the following medications or treatments within 3 months prior to screening: 1)Weight loss drugs, such as semaglutide, sibutramine hydrochloride, orlistat, phentermine, phenylpropanolamine, chlorpheniramine, phentermine, bupropion, lorcaserin, phentermine/topiramate mixture, naltrexone/bupropion mixture, etc.; 2)Chinese herbal medicine, health products, meal replacements affecting body weight; 3)Glucose-lowering drugs, such as metformin, SGLT2 inhibitors, GLP-1R agonists, thiazolidinediones (TZDs), etc; 4)Drugs that may affect body weight, including systemic (Consecutively for 7 or more days), tricyclic antidepressants, psychiatric drugs or sedative drugs (such as imipramine, amitriptyline, mirtazapine, paroxetine, phenelzine, chlorpromazine, thioridazine, clozapine, olanzapine, valproic acid, valproic acid derivatives, lithium salts);
  21. Previous bariatric surgery; acupuncture/cupping for weight loss, liposuction, and abdominal liposuction within 1 year prior to screening; or plan to undergo corresponding treatment during the study period;
  22. Subjects who have participated in other clinical studies and received investigational drug therapy, vaccines or medical device intervention within 3 months before screening;
  23. Blood donation or blood loss ≥ 400 mL within 3 months before screening, or those who have received blood transfusion;
  24. Inability to be venipunctured and/or tolerate venous access;
  25. Alcohol consumption of > 21 units per week for males and > 14 units per week for females within the 6 months before screening (1 unit=360 mL of beer or 45 mL of spirits with an alcohol content of ≥ 40% or 150 mL of wine);
  26. Have a history or suspected abuse of drug, and the investigator determines that the subject is unsuitable for this study;
  27. Have history of use of marijuana within 3 months before screening and unwillingness to abstain from marijuana use during the study;
  28. Pregnant or lactating women;
  29. Other conditions deemed unsuitable for participation in this study according to the judgment of the investigator..
Terms in these criteria, in plain language(21)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

TIA (transient ischaemic attack)

A “mini-stroke”: temporary stroke-like symptoms caused by reduced blood flow to part of the brain, spinal cord or eye, without signs of a new stroke on a scan.

Stroke symptoms need emergency care at once, even if they go away.

NYHA class (heart failure)

The New York Heart Association’s four classes of how much heart failure limits physical activity.

I
No limits: ordinary activity causes no undue tiredness or breathlessness.
II
Slight limits: comfortable at rest, ordinary activity causes symptoms.
III
Marked limits: comfortable at rest, less than ordinary activity causes symptoms.
IV
Symptoms even at rest; any activity makes them worse.

Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

HbA1c

A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

GFR and eGFR (kidney filtering)

GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².

Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.

INR, PT and aPTT (clotting tests)

Blood tests of how long blood takes to clot. The INR is the prothrombin time (PT) put on a common scale; about 1 is usual for someone not taking a blood thinner.

Criteria often make an exception for people on a blood thinner such as warfarin, whose INR is raised on purpose.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

QT and QTc

On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.

The study may name a correction formula and a limit in milliseconds, often around 450–480.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
200 participants (actual)

Study arms

  • Experimental
    Efsubaglutide 20 mg Quaque Week (QW)

    The drug is administered once weekly, starting with a titration dose of 1 mg. The dose is up-titrated every 2 weeks in the sequence of 1 mg → 5 mg → 10 mg → 20 mg, reaching the target dose of 20 mg, the total treatment last for 22weeks.

    Drug: Efsubaglutide Alfa 20 mg QW · Other: Placebo

  • Experimental
    Efsubaglutide 40 mg QW

    The drug is administered once weekly, starting with a titration dose of 1 mg. The dose is up-titrated every 2 weeks in the sequence of 1 mg → 5 mg → 10 mg → 20 → 40mg, reaching the target dose of 40 mg, the total treatment last for 22weeks.

    Drug: Efsubaglutide Alfa 40 mg QW · Other: Placebo

  • Experimental
    Efsubaglutide Alfa 40 mg Q2W

    The drug is administered once weekly, starting with a titration dose of 1 mg. The dose is up-titrated every 2 weeks in the sequence of 1 mg → 5 mg → 10 mg → 20 → 40mg,when reaching to target dose of 40 mg, administered the drug every 2weeks. the total treatment last for 22weeks.

    Drug: Efsubaglutide Alfa 40 mg Q2W · Other: Placebo

  • Experimental
    Efsubaglutide Alfa 80 mg QW

    The drug is administered once weekly, starting with a titration dose of 1 mg. The dose is up-titrated every 2 weeks in the sequence of 1 mg → 5 mg → 10 mg → 20 → 40mg→ 80mg, reaching the target dose of 80 mg, the total treatment last for 22weeks.

    Drug: Efsubaglutide Alfa 80 mg QW · Other: Placebo

  • Experimental
    Efsubaglutide Alfa 80 mg Q4W

    The drug is administered once weekly, starting with a titration dose of 1 mg. The dose is up-titrated every 2 weeks in the sequence of 1 mg → 5 mg → 10 mg → 20 → 40mg→ 80mg,when reaching to target dose of 80 mg, administered the drug every 4weeks. the total treatment last for 22weeks.

    Drug: Efsubaglutide Alfa 80 mg Q4W · Other: Placebo

Interventions

06

What researchers measure

Primary outcomes

  1. Percentage change (%) of body weight from baseline after subcutaneous administration of YN-011 for 22 weeks

    Time frame: 22 weeks

Secondary outcomes

  1. Proportion of subjects with body weight loss ≥ 5%, ≥ 10%, and ≥ 15% from baseline after subcutaneous

    Time frame: 22 weeks

  2. Absolute change from baseline in body weight (Kg) after subcutaneous administration for 22 weeks

    Time frame: 22 weeks

  3. Changes from baseline in BMI after subcutaneous administration for 22 weeks

    Time frame: 22 weeks

  4. Changes from baseline in waist to hip circumference ratio after subcutaneous administration for 22 weeks

    waist circumference, hip circumference,

    Time frame: 22 weeks

  5. Changes from baseline in waist to height ratio after subcutaneous administration of YN-011 for 22 weeks

    Time frame: 22 weeks

  6. Changes from baseline in systolic and diastolic blood pressure after subcutaneous administration for 22 weeks

    Time frame: 22 weeks

  7. Changes from baseline in blood lipids (including TC, TG, LDL-C, and high-density lipoprotein cholesterol [HDL-C]) after subcutaneous administration for 22 weeks, percentage change from baseline, and ratio to baseline

    Time frame: 22 weeks

  8. Changes from baseline in glycated hemoglobin (HbA1c) after administration subcutaneous for 22 weeks

    Time frame: 22 weeks

  9. Changes from baseline in fasting plasma glucose(FPG) after subcutaneous administration of YN-011 for 22 weeks;

    Time frame: 22 weeks

  10. Changes from baseline in fasting insulin after subcutaneous administration of YN-011 for 22 weeks;

    insulin resistance by HOMA-IR, β-cell function by HOMA-β,

    Time frame: 22 weeks

  11. Changes from baseline in blood uric acid after subcutaneous administration for 22 weeks, percentage change from baseline, and ratio to baseline

    Time frame: 22 weeks

  12. Safety assessment will be conducted throught the study by Incidence of adverse events (AEs) and serious adverse events (SAEs);

    Time frame: 22 weeks

  13. Safety assessment will be conducted throught the study by Mental health status via Patient Health Questionnaire-9 (PHQ-9)

    Time frame: 26 weeks

  14. Safety assessment will be conducted throught the study by Mental health status via Columbia Suicide Severity Rating Scale (C-SSRS)

    Time frame: 26 weeks

  15. Maximum plasma concentration (Cmax) of YN-011 via subcutaneous administration through the study

    Time frame: 22 weeks

  16. Timepoint of maximum plasma concentration (Tmax) of YN-011 via subcutaneous administration

    Time frame: 22 weeks

  17. Area under the concentration-time curve from the time zero to last measurable concentration (AUC0-t) of YN-011 via subcutaneous administration

    Time frame: 22 weeks

  18. Elimination half-life (t1/2) of YN-011 via subcutaneous administration

    Time frame: 22 weeks

  19. Apparent clearance (CL/F) of YN-011 via subcutaneous administration

    Time frame: 22 weeks

  20. Apparent volume of distribution (Vz/F) of YN-011 via subcutaneous administration

    Time frame: 22 weeks

  21. Trough concentration (Ctrough) of YN-011 via subcutaneous administration

    Time frame: 22 weeks

  22. Incidence of anti-drug antibody (ADA) against YN-011 in serum before and after subcutaneous administration

    Time frame: 22 weeks

  23. Incidence of neutralizing antibody (NAb) against YN-011 in serum before and after subcutaneous administration

    NAb will be tested when ADA result is positive

    Time frame: 22 weeks

  24. Changes from baseline in Dual Energy X-ray Absorptiometry [DEXA] data report (DEXA data inculding total fat mass, muscle mass, regional visceral fat mass and total lean body mass) after subcutaneous administration of YN-011

    Time frame: 22 weeks

07

Study locations

5 sites
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedDate before it movedWhere the date was before it movedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Aug 2025 to primary completion in Jul 2026, 10 months.

Of 131 non-industry phase 2 interventional studies under Obesity, half reached primary completion within 35 months of starting (the median), counting those still running; a quarter within 15 and three quarters within 57. This study's 10 months is below that.

Counting every sponsor, half of 307 studies reached it within 16 months; a quarter within 10 and three quarters within 35.

Since we started tracking on Sep 25, 2026, the dates moved once, on Nov 18, 2026: primary completion Jun 2026 → Jul 2026 and completion Aug 2026 → Jul 2026.

Earlier changes are on the record history on ClinicalTrials.gov ↗

How these figures are worked out, and which studies are left out of them.

Registered
Jul 6, 2025
First posted
Aug 11, 2025
StartActual
Aug 25, 2025
Primary completionActual
Jul 6, 2026was Jun 2026
CompletionActual
Jul 6, 2026was Aug 2026
Last update
Nov 18, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Status
Recruiting→Completed
changed Nov 18, 2026
Primary completion
Jun 1, 2026→Jul 6, 2026 (actual)
Nov 18, 2026
Study completion
Aug 1, 2026→Jul 6, 2026 (actual)
Nov 18, 2026
Show all 1 update
  1. Nov 18, 2026
    Recruiting→Completed
    Primary completion Jun 1, 2026→Jul 6, 2026 (now actual)
    Study completion Aug 1, 2026→Jul 6, 2026 (now actual)
    + 3 other changes: verification date, contact details and site details

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT07114419
Lead sponsor
Shanghai Yinnuo Pharmaceutical Technology Co., Ltd.
Responsible party
Sponsor
First posted
Aug 11, 2025
Start date
Aug 25, 2025
Primary completion
Jul 6, 2026
Completion
Jul 6, 2026
Last update
Nov 18, 2026

Study contacts

Karen Kaluhin
principal investigator · Canopy Clinical Sutherland Shire

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Nov 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Efsubaglutide alfa

Start the discussion